Belsomra

Chemical Namesuvorexant
Dosage FormTablet (oral; 5 mg, 10 mg, 15 mg, 20 mg)
Drug ClassReceptor antagonists
SystemNervous
CompanyMerck & Co.
Approval Year2014

Indication

  • For the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Last updated on 7/25/2022

More on this drug: Clinical Trials

Document TitleYearSource
Belsomra (suvorexant) Prescribing Information.2022Merck & Co., Rahway, NJ
Document TitleYearSource
Australian public assessment report for suvorexant.2018Australian Government: Department of Health

Have we missed a study, or would you like to comment on a study?